Floatz logo

482 assets in Prostate Cancer

Therapeutic assets addressing Prostate Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
H-Gamma1 Heavy Chain Homo Sapiens (1-447) [Vh (Homo Sapiens Ighv4-59*01 (99.0%) -(Ighd) -Ighj3*02 (93.3%) T125>I (114), Cdr-Imgt [8.7.11] (26-33.51-57.96-106)) (1-117) -Homo Sapiens Ighg1*01, G1M17,1 Ch1 K120, Ch3 D12, L14, 9-G1V21 Ch2 Y15.1, T16, E18 (Ch1 K120 (214) (118-215), Hinge 1-15 (216-230), Ch2 M15.1>Y (252), S16>T (254), T18>E (256) (231-340), Ch3 D12 (356), L14 (358) (341-445), Chs (446-447)) (118-447)], (220-214')-Disulfide With L-Kappa Light Chain Homo Sapiens (1'-214') [V-Kappa (Homo Sapiens Igkv3-11*01 (96.8%) -Igkj4*01 (100%), Cdr-Imgt [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo Sapiens Igkc*01 (100%) Km3 A45.1, V101 (Ckappa A45.1 (153'), V101 (191')) (108'-214')]; Dimer (226-226'':229-229'')-Bisdisulfide, Produced In A Cell Line Derived From Chinese Hamster Ovary (Cho) Cells, Glycoform Alfa
Prostate Cancer
Kineta Inc.P1/2CC (42)
Recombinant Ephb4-Hsa Fusion Protein
Prostate Cancer
Northwestern UniversityP2CC (42)
Copanlisib
Prostate Cancer
Memorial Sloan Kettering Cancer CenterP1/2CC (41)
hs-10502
Prostate Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd.P1CC (41)
hs-20089
Prostate Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd.P1CC (41)
Rivoceranib
Prostate Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd.P1CC (41)
ro7656594
Prostate Cancer
Genentech, Inc.P1CC (41)
[ 161 tb]tb psma i&t
Prostate Cancer
Peter MacCallum Cancer Centre, AustraliaP1/2CC (40)
[177Lu] Lu-XT033
Prostate Cancer
Sinotau Pharmaceutical GroupP1/2CC (40)
177Lu-rhPSMA-10.1
Prostate Cancer
M.D. Anderson Cancer CenterP1/2CC (40)
[²¹²pb]pb-advc001
Prostate Cancer
AdvanCell Pty LimitedP1/2CC (40)
225ac-lnc1011
Prostate Cancer
First Affiliated Hospital of Fujian Medical UniversityP1/2CC (40)
64cu-grip b
Prostate Cancer
Rahul AggarwalP1/2CC (40)
aaa602
Prostate Cancer
Novartis PharmaceuticalsP1/2CC (40)
aaa802
Prostate Cancer
Novartis PharmaceuticalsP1/2CC (40)
Ace-86225106
Prostate Cancer
Acerand Therapeutics (Shanghai) LimitedP1/2CC (40)
Actinium Rhpsma-10.1
Prostate Cancer
University College, LondonP1/2CC (40)
Allogeneic Adipose-Derived Mesenchymal Stem Cells
Prostate Cancer
The Methodist Hospital Research InstituteP1/2CC (40)
Amxi-5001
Prostate Cancer
AtlasMedx, IncorporatedP1/2CC (40)
Apl-5125
Prostate Cancer
Apollo Therapeutics LtdP1/2CC (40)
as1986ns
Prostate Cancer
Antelope Surgical Solutions, IncP1/2CC (40)
azd6621
Prostate Cancer
AstraZenecaP1/2CC (40)
azd9750
Prostate Cancer
AstraZenecaP1/2CC (40)
Bms 986253
Prostate Cancer
Mark SteinP1/2CC (40)
Camizestrant
Prostate Cancer
AstraZenecaP1/2CC (40)
Chadox1-Pcaq
Prostate Cancer
Barinthus BiotherapeuticsP1/2CC (40)
coq10
Prostate Cancer
University of NebraskaP1/2CC (40)
Datopotamab Deruxtecan
Prostate Cancer
AstraZenecaP1/2CC (40)
Disitamab
Prostate Cancer
Tianjin Medical University Second HospitalP1/2CC (40)
Envafolimab
Prostate Cancer
Tianjin Medical University Second HospitalP1/2CC (40)
Etx-19477
Prostate Cancer
858 Therapeutics, Inc.P1/2CC (40)
Fianlimab
Prostate Cancer
University of Wisconsin, MadisonP1/2CC (40)
Fog-001
Prostate Cancer
Parabilis Medicines, Inc.P1/2CC (40)
for46
Prostate Cancer
Rahul AggarwalP1/2CC (40)
Fractionated Dose Of 225Ac-J591
Prostate Cancer
Weill Medical College of Cornell UniversityP1/2CC (40)
ga-68-ngul
Prostate Cancer
Cellbion Co., Ltd.P1/2CC (40)
her2 fpbmc
Prostate Cancer
University of VirginiaP1/2CC (40)
Hrs-1167
Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.P1/2CC (40)
Hrs-6208
Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.P1/2CC (40)
inm176
Prostate Cancer
Milton S. Hershey Medical CenterP1/2CC (40)
inr102
Prostate Cancer
Yunhe Pharmaceutical (Tianjin) Co., LtdP1/2CC (40)
Lutetium Dgul
Prostate Cancer
Cellbion Co., Ltd.P1/2CC (40)
Lutetium Lu 177 Jh020002
Prostate Cancer
Bivision Pharmaceuticals, Inc.P1/2CC (40)
Masofaniten
Prostate Cancer
Pedro Barata, MD, MScP2CC (40)
mdx2001
Prostate Cancer
ModeX Therapeutics, An OPKO Health CompanyP1/2CC (40)
Mrt-2359
Prostate Cancer
Monte Rosa Therapeutics, IncP1/2CC (40)
mt-4561
Prostate Cancer
Tanabe Pharma America, Inc.P1/2CC (40)
Multiple Single Doses Of 225Ac-J591
Prostate Cancer
Weill Medical College of Cornell UniversityP1/2CC (40)
Mva-Pcaq
Prostate Cancer
Barinthus BiotherapeuticsP1/2CC (40)
Pocenbrodib
Prostate Cancer
Pathos AI, Inc.P1/2CC (40)
Showing 301 to 350 of 482 assets
PreviousPage 7 of 10Next